Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Nov 1;182(5):1609-14.
doi: 10.1084/jem.182.5.1609.

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein

Affiliations

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein

I Hara et al. J Exp Med. .

Abstract

The immune system can recognize differentiation antigens that are selectively expressed on malignant cells and their normal cell counterparts. However, it is uncertain whether immunity to differentiation antigens can effectively lead to tumor rejection. The mouse brown locus protein, gp75 or tyrosinase-related protein 1, is a melanocyte differentiation antigen expressed by melanomas and normal melanocytes. The gp75 antigen is recognized by autoantibodies and autoreactive T cells in persons with melanoma. To model autoimmunity against a melanocyte differentiation antigen, mouse antibodies against gp75 were passively transferred into tumor-bearing mice. Passive immunization with a mouse monoclonal antibody against gp75 induced protection and rejection of both subcutaneous tumors and lung metastases in syngeneic C57BL/6 mice, including established tumors. Passive immunity produced coat color alterations but only in regenerating hairs. This system provides a model for autoimmune vitiligo and shows that immune responses to melanocyte differentiation antigens can influence mouse coat color. Immune recognition of a melanocyte differentiation antigen can reject tumors, providing a basis for targeting tissue autoantigens expressed on cancer.

PubMed Disclaimer

References

    1. J Exp Med. 1995 Feb 1;181(2):799-804 - PubMed
    1. Lancet. 1994 Oct 15;344(8929):1049-52 - PubMed
    1. J Exp Med. 1982 Dec 1;156(6):1755-66 - PubMed
    1. J Exp Med. 1982 Dec 1;156(6):1884-9 - PubMed
    1. J Exp Med. 1983 Jul 1;158(1):246-51 - PubMed

Publication types

MeSH terms